These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2659740

  • 21. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S, Writing Committee of the "Bologna 90" Clinical Trial.
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [Abstract] [Full Text] [Related]

  • 22. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E.
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [Abstract] [Full Text] [Related]

  • 23. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H.
    Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
    [Abstract] [Full Text] [Related]

  • 24. High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients.
    Fermand JP, Ravaud P, Chevret S, Leblond V, Divine M, Dreyfus F, Belanger C, Troussard X, Mariette X, Brouet JC.
    Stem Cells; 1995 Aug; 13 Suppl 2():156-9. PubMed ID: 8520505
    [Abstract] [Full Text] [Related]

  • 25. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR, Fefer A, Thompson J, Case DC, Kempf R, Sacher R, Neefe J, Bickers J, Scarffe JH, Spiegel R.
    Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
    [Abstract] [Full Text] [Related]

  • 26. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
    Osterborg A, Ahre A, Björkholm M, Björeman M, Brenning G, Gahrton G, Gyllenhammar H, Johansson B, Juliusson G, Järnmark M.
    Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
    [Abstract] [Full Text] [Related]

  • 27. [Polychemotherapy in multiple myeloma. The COMPA protocol].
    Vázquez-Villegas V, Delgado Lamas JL, Romero-García F, Rodríguez-Carrillo J, Medina-Ruiz F.
    Rev Invest Clin; 1989 Jul; 41(4):345-50. PubMed ID: 2698501
    [Abstract] [Full Text] [Related]

  • 28. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA.
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [Abstract] [Full Text] [Related]

  • 29. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, Dimopoulos MA, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A.
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [Abstract] [Full Text] [Related]

  • 30. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [Abstract] [Full Text] [Related]

  • 31. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ.
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [Abstract] [Full Text] [Related]

  • 32. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, Cantonetti M, Carotenuto M, Comotti B, Dammacco F.
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [Abstract] [Full Text] [Related]

  • 33. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tarkovács G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A.
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [Abstract] [Full Text] [Related]

  • 34. [Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
    Paule B, Quillard J, Bisson M, Massias P.
    Nouv Rev Fr Hematol (1978); 1987 Nov; 29(6):391-6. PubMed ID: 2454453
    [Abstract] [Full Text] [Related]

  • 35. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF, Coltman CA, Bonnet JD, Cheson B.
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [Abstract] [Full Text] [Related]

  • 36. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T, Krykowski E, Płuzańska A, Olszańska-Skorek T, Urbańska-Ryś H, Polkowska-Kulesza E, Błasińska-Morawiec M, Mazurowa A.
    Pol Tyg Lek; 1983 Apr 18; 38(16):481-4. PubMed ID: 6579509
    [No Abstract] [Full Text] [Related]

  • 37. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
    Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, Greipp PR.
    Cancer; 2006 May 01; 106(9):1958-66. PubMed ID: 16565956
    [Abstract] [Full Text] [Related]

  • 38. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group Myelome-Autogreffe.
    J Clin Oncol; 2005 Dec 20; 23(36):9227-33. PubMed ID: 16275936
    [Abstract] [Full Text] [Related]

  • 39. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group.
    Cancer; 2008 Jan 01; 112(1):129-35. PubMed ID: 17973267
    [Abstract] [Full Text] [Related]

  • 40. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Jan 01; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.